



May 25, 2021

BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001.

The National Stock Exchange of India Limited

Exchange Plaza, Bandra-Kurla Complex
Bandra (E) Mumbai - 400 051.

Scrip code: 532531

Scrip code: STAR

Dear Madam/ Sir,

Ref: Company's press release of March 19, 2021 titled "Stelis concludes US\$ 195m Series B and Series C fund raise - Significant interest from marquee long term.

Sub: Disclosure under Regulation 30 of SEBI Listing Regulations

This has reference to the Company's press release referred above.

We now wish to inform you that Stelis has completed the **Series C round fund raising of USD 125 Million** (including secondary placement of USD 40 Million) from marquee long term investors led by TPG Growth followed by other long-term investors namely, Route One, Think Investments and the Mankekar Family.

The funds will be used by Stelis for:

- (a) Completion of last mile capex for the CDMO business including setting up of 6KL mammalian block, ramp up of process development lab and other technical capabilities;
- (b) Accelerating the vaccine block infrastructure with ability to cater to multiple vaccine types including viral vector, protein subunit, RNA and DNA;
- (c) Debt servicing and other general corporate purposes.

Consequent to the above transaction, Strides stake in Stelis now stands at 37.09% against 54.48% prior to the Series C funding.

Thanks & Regards,
For **Strides Pharma Science Limited**,

Manjula Ramamurthy
Company Secretary



Strides Pharma Science Limited

CIN: L24230MH1990PLC057062